India's tax authorities confirm ₹155 crore GST demand on Aurobindo Pharma
Change
India's Principal Commissioner of Customs and Central Tax (Appeals I), Hyderabad confirmed a combined GST demand, interest and penalty totalling ₹155,22,70,484 — including a ₹77,61,35,242 GST shortfall and an equal penalty — over alleged excess IGST refunds and non-reversal of input tax credit on exports from July 1, 2017 to March 23, 2020.
Why it matters
The confirmation makes the assessed tax and penalty an enforceable liability that can be collected unless an appellate stay is obtained. Corporate treasury and tax teams must therefore allocate liquidity or secure tribunal relief to prevent enforcement and running interest while the matter is contested.
Implications
- — Aurobindo Pharma's tax and finance teams must provision or pay the outstanding demand and penalties to avoid enforcement action and additional interest being levied.
- — Aurobindo Pharma's legal and tax teams must file an appeal at the Goods and Services Tax Appellate Tribunal (GSTAT) and seek a stay order if they intend to suspend collection while contesting the assessment.
Unlock the full brief.
Implications — what this forces you to change
Who is affected — which roles and obligations are exposed
What to watch — binding deadlines and enforcement dates
Real-time alerts — delivered the moment a binding change is published
Clarify with AI — turn any brief into a decision for your role
Start free trial
No credit card · $29/month (~₹2,400) after trial · Active in seconds
Source
View on The Hindu